Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Serplulimab is named as an intervention in 58 current clinical trials in our China and USA registers. 29 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Shanghai Henlius Biotech (9). The most-studied condition is Gastric Cancer.

Trials by status

Recruiting2950%
Not yet open1831%
Active, closed1017%
By invitation12%

Trials by phase

Phase 23866%
Phase 3610%
Phase 147%
Phase 2/335%
Phase 1/235%
Not applicable23%
Phase 412%
Observational12%

Clinical trials of Serplulimab

58 trials

Study	Phase	Status	Lead sponsor	Registers
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer NCT07113275 · ClinicalTrials.gov ↗ · Rectal Cancer, Total Neoadjuvant Therapy, Radiotherapy	Phase 3	Recruiting	Tao Zhang	China
Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma NCT07177443 · ClinicalTrials.gov ↗ · Locally Advanced Nasopharyngeal Carcinoma	Phase 3	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer NCT07739758 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 3	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	China
A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) NCT04547166 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2/3	Recruiting	Shanghai Henlius Biotech	China
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients NCT06280495 · ClinicalTrials.gov ↗ · Colorectal Cancer, Liver Metastases	Phase 2/3	Recruiting	Sun Yat-sen University	China
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer NCT05731726 · ClinicalTrials.gov ↗ · pMMR, MSS, MSI-L	Phase 2	Recruiting	Zhejiang University	China
Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases NCT05742425 · ClinicalTrials.gov ↗ · Unresectable Colon Cancer Peritoneal Metastases, PMMR/Ras/BRAF Wild-type	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer NCT05766800 · ClinicalTrials.gov ↗ · Locally Advanced, Non-small Cell Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05) NCT05872685 · ClinicalTrials.gov ↗ · Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair	Phase 2	Recruiting	Yu jiren	China
Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer NCT05975749 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	Fudan University	China
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. NCT06349980 · ClinicalTrials.gov ↗ · Carcinoma, Hepatocellular	Phase 2	Recruiting	Shanghai Henlius Biotech	China
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age NCT06354218 · ClinicalTrials.gov ↗ · Esophageal Carcinoma	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma NCT06461910 · ClinicalTrials.gov ↗ · Gastric Cancer, Esophagogastric Junction Adenocarcinoma	Phase 2	Recruiting	Zekuan Xu	China
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC NCT06497530 · ClinicalTrials.gov ↗ · Extensive-Stage Small Cell Lung Cancer	Phase 2	Recruiting	Guangzhou Institute of Respiratory Disease	China
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC NCT06601309 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases NCT06850103 · ClinicalTrials.gov ↗ · Colorectal Carcinoma, Oligometastases, pMMR	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer NCT06860529 · ClinicalTrials.gov ↗ · HR+/HER2- Breast Cancer	Phase 2	Recruiting	Henan Cancer Hospital	China
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) NCT07150949 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer, Neoadjuvant Therapy	Phase 2	Recruiting	Fudan University	China
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) NCT07283692 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 2	Recruiting	RenJi Hospital	China
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC NCT07398937 · ClinicalTrials.gov ↗ · Resectable Stage II-IIIa Squamous NSCLC	Phase 2	Recruiting	Fudan University	China
Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC NCT07457528 · ClinicalTrials.gov ↗ · Resectable Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard Therapy NCT07506057 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Biliary Tract Cancer, HER2	Phase 2	Recruiting	Xiujuan Qu	China
Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50% NCT07596121 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)	Phase 2	Recruiting	Tang-Du Hospital	China
A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy NCT07604909 · ClinicalTrials.gov ↗ · Colorectal Cancer, Relapse	Phase 2	Recruiting	Fudan University	China
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors NCT06302062 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Tumor Associated Lymph Node T Cell, Immunotherapy	Phase 1	Recruiting	Guangzhou FineImmune Biotechnology Co., LTD.	China
A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors NCT06716619 · ClinicalTrials.gov ↗ · Tumor Associated Lymph Node T Cell, Advanced Solid Tumor, Immunotherapy	Phase 1	Recruiting	Guangzhou FineImmune Biotechnology Co., LTD.	China
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer NCT07231445 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 1	Recruiting	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. NCT06781281 · ClinicalTrials.gov ↗ · Breast Cancer Invasive	Observational	Recruiting	Henan Cancer Hospital	China
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer NCT06128252 · ClinicalTrials.gov ↗ · Gastric Cancer	Not applicable	Recruiting	Tang-Du Hospital	China
FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer NCT07446465 · ClinicalTrials.gov ↗ · Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS)	Phase 4	Not yet open	Ye Xu	China
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer NCT07277842 · ClinicalTrials.gov ↗ · Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)	Phase 3	Not yet open	Sun Yat-sen University	China
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer NCT07318883 · Squamous NSCLC	Phase 2/3	Not yet open	Shanghai Henlius Biotech	China
Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) NCT05988372 · ClinicalTrials.gov ↗ · Locally Advanced Pancreatic Cancer	Phase 2	Not yet open	Sun Yat-sen University	China
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation NCT06531291 · ClinicalTrials.gov ↗ · ESCC, Biliary Tract Cancer, Gastric Cancer	Phase 2	Not yet open	RenJi Hospital	China
Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX NCT07391826 · ClinicalTrials.gov ↗ · Stage III Gastric Cancer	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC NCT07403435 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer NCT07466303 · ClinicalTrials.gov ↗ · Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer	Phase 2	Not yet open	Xijing Hospital	China
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer. NCT07487519 · ClinicalTrials.gov ↗ · Breast Cancer (Triple Negative Breast Cancer (TNBC))	Phase 2	Not yet open	Shanghai Henlius Biotech	China
Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-risk pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Multi-center Randomized Control Phase II Trial NCT07527520 · ClinicalTrials.gov ↗ · Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab	Phase 2	Not yet open	Fudan University	China
A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer NCT07543848 · ClinicalTrials.gov ↗ · Rectal Neoplasms, Rectal Adenocarcinoma	Phase 2	Not yet open	Chongqing University Cancer Hospital	China
A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance NCT07622550 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC)	Phase 2	Not yet open	Jiangsu Cancer Institute & Hospital	China
Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer NCT07691632 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer, Colorectal Adenocarcinoma	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) NCT07713745 · ClinicalTrials.gov ↗ · Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma	Phase 2	Not yet open	Beijing Tiantan Hospital	China
JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure NCT07175389 · ClinicalTrials.gov ↗ · Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Adenocarcinoma	Phase 1/2	Not yet open	West China Hospital	China
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer NCT07358585 · ClinicalTrials.gov ↗ · Colon Cancer Adenocarcinoma	Phase 1/2	Not yet open	Shanghai Henlius Biotech	China
Luvometinib in Combination With Serplulimab for NF2-Related Tumors NCT07708285 · ClinicalTrials.gov ↗ · NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2	Phase 1/2	Not yet open	Beijing Tiantan Hospital	China
Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer NCT06580665 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Not applicable	Not yet open	Shanghai Chest Hospital	China
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors NCT06115642 · ClinicalTrials.gov ↗ · Advanced/Metastatic Malignant Solid Tumors	Phase 1	By invitation	Shanghai Henlius Biotech	USA, China
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer NCT05353257 · Limited-Stage Small Cell Lung Cancer	Phase 3	Active, closed	Shanghai Henlius Biotech	USA, China
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC NCT05468489 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer	Phase 3	Active, closed	Shanghai Henlius Biotech	USA
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC NCT05513573 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma by AJCC V8 Stage	Phase 2	Active, closed	Shanghai Henlius Biotech	China
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy NCT05585580 · ClinicalTrials.gov ↗ · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	Qilu Hospital of Shandong University	China
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC NCT05765825 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Active, closed	Sichuan University	China
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer NCT05882513 · ClinicalTrials.gov ↗ · NSCLC, Neoadjuvant Therapy	Phase 2	Active, closed	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer NCT06394661 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	Henan Cancer Hospital	China
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction NCT06576921 · ClinicalTrials.gov ↗ · Stomach Neoplasms, Immune Checkpoint Inhibitors	Phase 2	Active, closed	Xijing Hospital	China
A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma NCT07257575 · ClinicalTrials.gov ↗ · Gastric Cancer Stage III	Phase 2	Active, closed	Guangdong Provincial People's Hospital	China
Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma NCT07488533 · ClinicalTrials.gov ↗ · Non-Clear Cell Renal Cell Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Serplulimab

85 conditions

Gastric Cancer4Immunotherapy3Rectal Cancer2pMMR2MSS2Non-small Cell Lung Cancer2Colorectal Cancer2Advanced Solid Tumor2Tumor Associated Lymph Node T Cell2Breast Cancer2Biliary Tract Cancer2Neurofibromatosis Type 22

All 85 conditions

Condition (as registered)	Trials
Gastric Cancer	4
Immunotherapy	3
Rectal Cancer	2
pMMR	2
MSS	2
Non-small Cell Lung Cancer	2
Colorectal Cancer	2
Advanced Solid Tumor	2
Tumor Associated Lymph Node T Cell	2
Breast Cancer	2
Biliary Tract Cancer	2
Neurofibromatosis Type 2	2
Vestibular Schwannoma	2
Neoadjuvant Therapy	2
Limited-Stage Small Cell Lung Cancer	1
Advanced/Metastatic Malignant Solid Tumors	1
Squamous NSCLC	1
Nasopharyngeal Carcinoma by AJCC V8 Stage	1
Carcinoma, Hepatocellular	1
Total Neoadjuvant Therapy	1
Radiotherapy	1
MSI-L	1
Locally Advanced Rectal Carcinoma	1
Metastatic Colorectal Cancer	1
Resectable Esophageal Squamous Cell Carcinoma	1
Breast Cancer (Triple Negative Breast Cancer (TNBC))	1
Extensive Stage Small Cell Lung Cancer	1
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	1
Small Cell Lung Cancer	1
Colorectal Cancer (Locally Advanced or Metastatic)	1
Colorectal Cancer Microsatellite Stable (MSS)	1
Resectable Stage II-IIIa Squamous NSCLC	1
Gastric Cancer Stage III	1
Esophageal Squamous Cell Carcinoma (ESCC)	1
Extensive-Stage Small Cell Lung Cancer	1
Breast Cancer Invasive	1
Locally Advanced Nasopharyngeal Carcinoma	1
Metastatic Colorectal Cancer (CRC)	1
HR+/HER2- Breast Cancer	1
Esophageal Carcinoma	1
Esophageal Squamous Cell Carcinoma	1
Locally Advanced	1
Liver Metastases	1
Locally Advanced Low Rectal Adenocarcinoma	1
pMMR (Microsatellite Stable Rectal Cancer)	1
Extensive-stage Small-cell Lung Cancer	1
Refractory Pancreatic Ductal Adenocarcinoma	1
Refractory Pancreatic Adenocarcinoma	1
Unresectable Colon Cancer Peritoneal Metastases	1
PMMR/Ras/BRAF Wild-type	1
Esophagogastric Junction Adenocarcinoma	1
Rectal Neoplasms	1
Rectal Adenocarcinoma	1
NSCLC (Non-small Cell Lung Cancer)	1
Adenocarcinoma of the Stomach	1
Adenocarcinoma of Esophagogastric Junction	1
Proficient Mismatch Repair	1
Colon Cancer Adenocarcinoma	1
Serplulimab Injection	1
Locally Advanced Pancreatic Cancer	1
Non-Clear Cell Renal Cell Carcinoma	1
Urothelial Carcinoma	1
HER2	1
Triple Negative Breast Cancer	1
ESCC	1
Pancreas Cancer	1
Relapse	1
NF2-related Schwannomatosis	1
NF2	1
Stomach Neoplasms	1
Immune Checkpoint Inhibitors	1
Locally Advanced Rectal Cancer	1
Colorectal Carcinoma	1
Oligometastases	1
Moderately Hypofractionated Radiotherapy	1
Serplulimab	1
pMMR/MSS	1
Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer	1
SCLC, Extensive Stage	1
Locally Advanced Colorectal Cancer	1
Colorectal Adenocarcinoma	1
Non-vestibular Schwannoma	1
Meningioma	1
Stage III Gastric Cancer	1
NSCLC	1

By country register

Register	Trials	Recruiting
Clinical trials in China	57	29
Clinical trials in USA	3	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Serplulimab trials

How many clinical trials are testing Serplulimab?

58 current trials in our China and USA registers name Serplulimab (also registered as HLX10) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Serplulimab trials recruiting patients?

Yes. 29 of the 58 trials are recruiting: 29 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Serplulimab clinical trials?

Shanghai Henlius Biotech (9), Fudan University (5), Sun Yat-sen University (4) and Henan Cancer Hospital (3), among 32 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Serplulimab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Serplulimab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Serplulimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Serplulimab clinical trials